Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. ONGLYZA (saxagliptine)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

ONGLYZA (saxagliptine)

Medicine - Posted on Aug 30 2021
Active substance (DCI)
  • saxagliptine
history (5)
  • 7/21/21

    ONGLYZA (saxagliptine (chlorhydrate de))

    Key points The Committee reassessed 12 proprietary medicinal products containing 5 different gliptin substances, including 6...
    CAV :
    54321
    icône flèche
  • 7/1/15

    ONGLYZA (saxagliptine)

    Maintien du remboursement dans les mêmes conditions à l'exception de l'utilisation en monothérapie : avis défavorable au rem...
    icône flèche
  • 7/23/14

    ONGLYZA (saxagliptin),

    No clinical benefit demonstrated for saxagliptin in combination with metformin and a sulfonylurea ONGLYZA has Marketing Auth...
    CAV :
    54321
    icône flèche
  • 5/15/13

    ONGLYZA

    -
    CAV :
    54321
    icône flèche
  • 12/2/09

    ONGLYZA

    Pas d’avantage clinique démontré dans le traitement du diabète de type 2 ONGLYZA est indiqué dans le traitement du diabète d...
    CAV :
    54321
    icône flèche
Technical information
ATC code
  • A10BH03
Manufacturer
ASTRAZENECA
Presentation

ONGLYZA 5 mg, comprimé pelliculé (code CIS : 66862731)
30 plaquette(s) thermoformée(s) aluminium de 1 comprimé(s) pré-découpées (Code CIP : 34009 397 358 8 7)
90 plaquette(s) thermoformée(s) aluminium de 1 comprimé(s) pré-découpées (Code CIP : 34009 575 956 3 0)

All our publications
    Diabetes mellitus Drug therapy

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
eNq1mF1v2jAUhu/5FVHuSQilBaZAtTG6IbUao0WbdlOZ5ABmrp36g4/++jmEamFy1NXgy9jOOSc+rx+/Sny9fSLeGrjAjPb8KGj4HtCEpZguev704abe8a/7tXiF1qi0rB00gqjpewlBQvT8fDaYAaIi+Hl3+xn0+8D9fs2L2WwFiTxapyQmwVcklncoy9d48Zrh1HsCuWRpz8+U3I96sZBcV9HfMP5bZCiBODyMlGdXj63yeBzmwf4jqhLAbxFdGIMCtYqZKM6BygGSsGB8V1HvhVVsLCYgmOIJjJFcjjlb4xRSY4o5IgKsksw36T3wNQGZJzEGD1fJk7AKjlZoO4Hnkbnoj3p2ILey3qhH7Vb3IrrqdtudRmSVipe2ytwF/RFhlvH0sdnttFqtZgg0ZHRBdi+oLtAWLQjOJKZg2asx4xIRR13CYnAsNEd5ODy/qYYUi4ygXbASme1WIY70NHCNA3cfkn/BA9eAInrP/olPFSHhO6ueHvDhqOKcTgOmqKygyM3EdiMGjErYVnfUDnxye9AiBnG+sC+MmqE/VjOCE1vEaQgpEHI6GVUTziUcPiEBU+6ODj8wTdlGnJ865S47qj7bg9MYVDckyjtyFV1eWh+qX1pSFTfQUHGWQah5hMUpmBnROTsVMFql5lCvGnUmz70vYgkiUOGM6pbs0bp8NXLOlO/uVBUTxqBfhg+2cvmugO/u94/G0DjtlRttx2YXwNf6rKz9/WovDr0T26y4GSZLKTPxIQw3m02wREKfG71LwZw7h3/p/nVn4p1c8oXpKQDqqPRZcTO+r2O2h+8tG3CqtT28f7DQxhySKzihFwWnndF0NDw/oP/6Wmdlj49o4i7N3oMiiRl15YXUzGyETr0SdGvpDdeM+Daf44r/KpXSjMPin06/Fof5/5x+7Q+f5wIG
5PHh0v3M7pGC8AVv